Tag Archives: Remicade
Merck/Schering-Plough Merger Highlights (Update 1)
Merck and Schering-Plough’s CEOs are giving a run down of the benefits of the $41.1 billion merger, announced this morning, in a conference call with investors. Here are some of the highlights:
• Total price of the sale will be $41.1 billion or $23.6 per Schering share.
• This deal is structured as a reverse merger with [...]
Posted in Deals, Strategy Also tagged Deal, Johnson & Johnson, Merck, Merger, Schering Plough, Vytorin 4 Comments

FDA Strengthens Warnings on TNF Inhibitors